Alpha Tau Medical Ltd. has announced final results from its first-in-human pancreatic cancer study in Montreal, Canada, evaluating the use of its Alpha DaRT® alpha-radiation therapy for pancreatic ductal adenocarcinoma (PDAC). The study demonstrated an 81% disease control rate, or 87% when excluding the first two patients treated. Immune marker analysis indicated preservation of immune system function and a potential anti-inflammatory effect, which is not typical of conventional radiation therapy. The results have been published as two abstracts and will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco. Alpha DaRT is also currently being studied in combination with first-line chemotherapy in the U.S. multi-center IMPACT trial for newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma, as well as in other clinical studies in Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619416-en) on January 06, 2026, and is solely responsible for the information contained therein.